Provided By GlobeNewswire
Last update: Mar 19, 2025
ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces a partnership with CNY Fertility, a national provider of fertility services across the U.S. CNY Fertility will provide the Company’s FemaSeed intratubal insemination product as an infertility treatment option to patients throughout its network of 11 locations.
Read more at globenewswire.comNASDAQ:FEMY (4/25/2025, 8:05:42 PM)
1.23
-0.01 (-0.81%)
Find more stocks in the Stock Screener